Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: A pilot study

Diabetologia

Volumn 53, Issue 7, 2010, Pages 1304-1313

  Arafat, A M ^a,b   Mohlig M ^a,b   Weickert, M O ^b,c,e   Schofl C ^d   Spranger, J ^a,b   Pfeiffer, A F H ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c Warwickshire Institute for Study of Diabetes Endocrinology and Metabolism   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Beta cell function; C peptide; Euglycaemic hyperinsulinaemic clamp; Growth hormone deficiency; Growth hormone replacement therapy; Hyperglycaemic clamp; Insulin; Insulin clearance; Insulin sensitivity; Oral glucose tolerance test

Indexed keywords

ARGININE; C PEPTIDE; GLUCOSE; HUMAN GROWTH HORMONE; INSULIN; SOMATOMEDIN C;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG RESPONSE; EVENING DOSAGE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LONG TERM CARE; LOW DRUG DOSE; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE;

ADULT; C-PEPTIDE; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 77955653662     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1738-4     Document Type: Article

References (50)

1. Simpson H, Savine R, Sonksen P et al (2002) Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res 12:1-33.
2. Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431.
3. Erfurth EM, Bulow B, Eskilsson J, Hagmar L (1999) High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Growth Horm IGF Res 9(Suppl A):21-24.
4. Rosenfalck AM, Fisker S, Hilsted J et al (1999) The effect of the deterioration of insulin sensitivity on beta-cell function in growthhormone-deficient adults following 4-month growth hormone replacement therapy. Growth Horm IGF Res 9:96-105.
5. Weaver JU, Monson JP, Noonan K et al (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80: 153-159.
6. Yuen K, Cook D, Ong K et al (2002) The metabolic effects of short-term administration of physiological vs high doses of GH therapy in GH deficient adults. Clin Endocrinol (Oxf) 57: 333-341.
7. Yuen KC, Dunger DB (2007) Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 9:11-22.
8. O'Neal DN, Kalfas A, Dunning PL et al (1994) The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 79:975-983.
9. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML (2005) Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 63:310-316.
10. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 60:442-450.
11. Bulow B, Erfurth EM (1999) A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance. Clin Endocrinol (Oxf) 50:45-55.
12. Yuen KC, Frystyk J, White DK et al (2005) Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 63:428-436.
13. Yuen KC, Dunger DB (2006) Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency. Clin Endocrinol (Oxf) 64:549-555.
14. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB (2005) One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 152:67-75.
15. Hugl SR, White MF, Rhodes CJ (1998) Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem 273:17771-17779.
16. Rhodes CJ (2000) IGF-I and GH post-receptor signaling mechanisms for pancreatic beta-cell replication. J Mol Endocrinol 24:303-311.
17. Kulkarni RN, Holzenberger M, Shih DQ et al (2002) Beta-cellspecific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 31:111-115.
18. Xuan S, Kitamura T, Nakae J et al (2002) Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 110:1011-1019.
19. Liu W, Chin-Chance C, Lee EJ, Lowe WL Jr (2002) Activation of phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition of pancreatic beta-cell death. Endocrinology 143:3802-3812.
20. Ahren B, Thorsson O (2003) Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. J Clin Endocrinol Metab 88:1264-1270.
21. Yuen K, Wareham N, Frystyk J et al (2004) Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur J Endocrinol 151: 39-45.
22. Acerini CL, Cheetham TD, Edge JA, Dunger DB (2000) Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 43:61-68.
23. Lucidi P, Lauteri M, Laureti S et al (1998) A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 83:353-357.
24. Fowelin J, Attvall S, Lager I, Bengtsson BA (1993) Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42:1443-1447.
25. Diamond MP, Simonson DC, DeFronzo RA (1989) Menstrual cyclicity has a profound effect on glucose homeostasis. Fertil Steril 52:204-208.
26. Haffner SM, Karhapaa P, Mykkanen L, Laakso M (1994) Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43:212-219.
27. Arafat AM, Mohlig M, Weickert MO et al (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93:1254-1262.
28. Arafat AM, Weickert MO, Frystyk J, et al (2009) The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 94:5093-5101.
29. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223.
30. Veening MA, van Weissenbruch MM, Heine RJ, Delemarre-van de Waal HA (2003) Beta-cell capacity and insulin sensitivity in prepubertal children born small for gestational age: influence of body size during childhood. Diabetes 52:1756-1760.
31. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654-664.
32. Polonsky KS, Rubenstein AH (1984) C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 33:486-494.
33. Polonsky KS, Given BD, Hirsch L et al (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81:435-441.
34. Mittelman SD, Van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49:2116-2125.
35. Alberti KGM, Zimmet P, Shaw J (2005) The metabolic syndrome-a new worldwide definition. The Lancet 366:1059-1062.
36. Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L (2003) Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 88:1455-1463.
37. Hansen TK, Gravholt CH, Orskov H, Rasmussen MH, Christiansen JS, Jorgensen JO (2002) Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 87:4691-4698.
38. Biasotti A, Houssay BA (1932) Phlorrhizin diabetes in fasting or fed hypophysectomized dogs. J Physiol 77:81-91.
39. Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663-669.
40. Nielsen S, Moller N, Christiansen JS, Jorgensen JO (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50:2301-2308.
41. Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC (2001) Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 86:5813-5818.
42. Yuen K, Ong K, Husbands S et al (2002) The effects of short-term administration of two low doses vs the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults. J Clin Endocrinol Metab 87:1989-1995.
43. Plockinger U, Reuter T (2008) Pegvisomant increases intraabdominal fat in patients with acromegaly: a pilot study. Eur J Endocrinol 158:467-471.
44. Davidson MB (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8:115-131.
45. Press M (1988) Growth hormone and metabolism. Diabetes Metab Rev 4:391-414.
46. Yuen KC, Dunger DB (2006) Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res 16(Suppl A):S55-S61.
47. Pierluissi J, Campbell J (1980) Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals. Diabetologia 18:223 228.
48. Wiesli P, Schaffler E, Seifert B, Schmid C, Donath MY (2004) Islets secretory capacity determines glucose homoeostasis in the face of insulin resistance. Swiss Med Wkly 134:559-564.
49. Beshyah SA, Henderson A, Niththyananthan R et al (1995) The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 80:356-363.
50. Hother-Nielsen O, Henriksen JE, Holst JJ, Beck-Nielsen H (1996) Effects of insulin on glucose turnover rates in vivo: isotope dilution vs constant specific activity technique. Metabolism 45:82-91.